Myeloma remains largely incurable and there is an unmet need for new therapies. B-cell
maturation antigen (BCMA) is an attractive therapeutic target due to its restricted expression …

Immune based strategies have shown early promise in multiple myeloma (MM), and are
likely to prove a valuable addition to the therapeutic platforms for these patients. B cell …

B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma
(MM), but expression is variable, and early reports of BCMA targeting chimeric antigen …

Existing immunotherapies for multiple myelomas (MM), including bispecific antibodies,
antibody-drug conjugates and chimeric antigen receptor-based strategies, have targeted the …

A proliferation-inducing ligand (APRIL), a close member of B-cell-activating factor (BAFF)
belonging to the TNF superfamily that stimulates growth and survival of multiple myeloma …

Multiple myeloma (MM) is an aggressive incurable plasma cell malignancy with a median
life expectancy of less than seven years. Antibody-based therapies have demonstrated …

Introduction: A hallmark of multiple myeloma (MM) is the low levels of uninvolved
immunoglobulin (Ig) levels. B-cell maturation antigen (BCMA) is a receptor expressed in …

Background: Targeting BCMA (B-cell maturation factor) with chimeric antigen receptor
(CAR) T cells has shown great success in the treatment of multiple myeloma (MM), but is …

The treatment of multiple myeloma (MM) has entered into a new era of immunotherapy.
Novel immunotherapies will significantly improve patient outcome via simultaneously …

The B Cell Maturation Antigen (BCMA) is present in nearly all Multiple Myeloma cells and
serves as a potential biomarker for identifying malignant plasma cells as well as a target for …